• PCN255 - CERVICAL AND BREAST CANCER IN KAZAKHSTAN BEFORE AND AFTER THE INTRODUCTION OF SCREENING- AN INTERRUPTED TIME SERIES ANALYSIS

    Oct 1, 2018, 00:00

  • PND39 - MULTIPLE SCLEROSIS BURDEN OF ILLNESS STUDY FOR TURKEY

    Oct 1, 2018, 00:00

  • PMS48 - COST PER RESPONDER ANALYSIS FOLLOWING A 24-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ETANERCEPT FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP354 - THE IMPACT OF DATA PRIVACY REGULATIONS ON DRUG UTILIZATION DATA SHARING FOR INNOVATIVE PRICING ARRANGEMENTS

    Oct 1, 2018, 00:00

  • PHP97 - NONADHERENCE TO TACROLIMUS IN ADULT LIVER AND KIDNEY TRANSPLANTATION IS ASSOCIATED WITH A HIGHER RISK OF EFFICACY FAILURE- REAL-WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASES

    Oct 1, 2018, 00:00

  • CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCE

    Oct 1, 2018, 00:00

  • PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE- FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)

    Oct 1, 2018, 00:00

  • PIH53 - COMPARISON OF THE EQ-5D-5L AND THE EQ-5D-3L USING INDIVIDUAL PATIENT DATA FROM REFORM TRIAL

    Oct 1, 2018, 00:00

  • PHP132 - CAN BLOCKCHAIN TECHNOLOGY IMPROVE THE QUALITY OF CLINICAL TRIAL EVIDENCE? – A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB10 - MACROVASCULAR AND MICROVASCULAR COMPLICATIONS OF TYPE 2 DIABETES MELLITUS AND ITS ASSOCIATED FREQUENCY OF HOSPITAL ADMISSION

    Oct 1, 2018, 00:00

  • PCN236 - IMPLICATIONS OF THE FAST EVOLVING THERAPEUTIC LANDSCAPE ON APPROPRIATE COMPARATORS IN ONCOLOGICAL AMNOG BENEFIT ASSESSMENTS

    Oct 1, 2018, 00:00

  • PCN384 - HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPY

    Oct 1, 2018, 00:00

  • PDB45 - COSTS OF PREVENTION, MONITORING AND TREATMENT OF IODINE DEFICIENCY DISORDERS IN GERMANY

    Oct 1, 2018, 00:00

  • PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK

    Oct 1, 2018, 00:00

  • PMS65 - MYOTONIC DISORDERS- ANALYSIS FROM THE FRENCH DRG-BASED INFORMATION SYSTEM (PMSI)

    Oct 1, 2018, 00:00

  • PND99 - CYSTIC FIBROSIS THERAPIES - KEY DRIVERS BEHIND DIFFERING HTA DECISIONS

    Oct 1, 2018, 00:00

  • PSS55 - COMPARATIVE EFFECTIVENESS OF INTEGRATED LOCAL TREATMENTS OF GENERALIZED PERIODONTITIS AND CHRONIC GINGIVITIS

    Oct 1, 2018, 00:00

  • PSY122 - MANAGEMENT OF POOR PROGNOSIS MULTIPLE MYELOMA PATIENTS UNDER REGULAR CLINICAL CONDITIONS IN SPAIN

    Oct 1, 2018, 00:00

  • PIN71 - ADENOVIRUS VIREMIA IS AN INDEPENDENT PREDICTOR OF PROLONGED TRANSPLANTATION HOSPITALIZATION IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS- FINDINGS FROM ADVANCE

    Oct 1, 2018, 00:00

  • PDB3 - THE IMPACT OF GLYCATED HEMOGLOBIN CONTROL ON MORBIDITY AND SURVIVAL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PRM66 - AN EXPLORATION OF THE METHODOLOGY FOR CONSIDERING TREATMENT DURATION IN BUDGET IMPACT ANALYSES IN ONCOLOGY- A CASE STUDY IN SECOND LINE ADVANCED RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PND59 - COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN GREECE

    Oct 1, 2018, 00:00

  • PRS54 - COST-EFFECTIVENESS ANALYSIS OF RESLIZUMAB FOR PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA INADEQUATELY CONTROLLED WITH HIGH-DOSE INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONISTS IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PHP225 - ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS- THE EXAMPLE OF MRI AND CT-SCAN ACTS IN FRANCE

    Oct 1, 2018, 00:00

  • PCV5 - REAL-WORLD LDL-C CHANGES EXPERIENCED WITH LOMITAPIDE MODELLED TO POTENTIALLY INCREASE LIFE-EXPECTANCY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

    Oct 1, 2018, 00:00

  • PMD64 - THE ROLE OF INFORMATION PROVISION IN ECONOMIC EVALUATIONS OF NON-INVASIVE PRENATAL TESTING- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PIH54 - A GLOBAL REVIEW OF QUALITY OF LIFE IMPACT OF ATOPIC DERMATITIS IN CHILDREN

    Oct 1, 2018, 00:00

  • PMD31 - THE CONCORDANCE AND BUDGET IMPACT OF MULTIPLE ER, PR AND HER2 DETERMINATIONS IN DUTCH BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PRS24 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI AND UMEC/VI IN PATIENTS WITH COPD- HEALTHCARE RESOURCE UTILIZATION DATA AND ASSOCIATED COSTS – GERMANY

    Oct 1, 2018, 00:00

  • PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS- AN ONTARIO, CANADA ANALYSIS

    Oct 1, 2018, 00:00

  • PCN73 - BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN RUSSIA

    Oct 1, 2018, 00:00

  • PDB94 - INITIAL ANTIDIABETIC PHARMACOTHERAPY PRESCRIBED TO PATIENTS WITH NEWLY DIAGNOSED TYPE-2 DIABETES IN A COMMERCIAL HEALTH PLAN IN THE UNITED STATED

    Oct 1, 2018, 00:00

  • PMS5 - A NETWORK META-ANALYSIS TO EVALUATE THE EFFICACY OF BARICITINIB AND OTHER TREATMENTS OF RHEUMATOID ARTHRITIS IN PATIENTS WHO ARE INADEQUATE RESPONDERS TO METHOTREXATE

    Oct 1, 2018, 00:00

  • PND3 - SYSTEMATIC LITERATURE REVIEW ON THE EFFICACY AND SAFETY OF ANTIEPILEPTIC DRUGS IN PAEDIATRIC PATIENTS WITH FOCAL SEIZURES – ARE CURRENTLY APPROVED THERAPIES SUFFICIENT FOR THE MANAGEMENT OF PAEDIATRIC PATIENTS?

    Oct 1, 2018, 00:00

  • PMD16 - HEALTH ECONOMIC EVALUATION OF AN ULTRATHIN, BIORESORBABLE POLYMER SIROLIMUS-ELUTING CORONARY STENT COMPARED TO A THIN, DURABLE POLYMER EVEROLIMUS-ELUTING STENT

    Oct 1, 2018, 00:00

  • PRM232 - LONGITUDINAL MATCHING- A METHOD FOR GENERATING COMPARABLE SAMPLES OF TREATED AND TREATMENT-NAÏVE PATIENTS WITH PROGRESSIVE CONDITIONS

    Oct 1, 2018, 00:00

  • PHP200 - A REVIEW OF ACHIEVEMENTS AND CHALLENGES OF IRAN’S HEALTH TRANSFORMATION PLAN

    Oct 1, 2018, 00:00

  • PND104 - RECOMMENDATIONS FOR A NATIONAL MULTIPLE SCLEROSIS (MS) STRATEGY

    Oct 1, 2018, 00:00

  • PDB61 - COST-EFFECTIVENESS ANALYSIS OF HUMAN OR ANALOGUE BASAL INSULIN-SUPPORTED ORAL THERAPY IN TYPE 2 DIABETES IN HUNGARY

    Oct 1, 2018, 00:00

  • PCN377 - RESPONSE SHIFT EFFECT ON QUALITY OF LIFE IN RANDOMIZED CONTROL TRIAL OF TAXANE VERSUS S-1 FOR METASTATIC BREAST CANCER PATIENTS (SELECT-BC)- STRUCTURAL EQUATION MODELING

    Oct 1, 2018, 00:00

  • PMD32 - HOW CHANGES IN ELECTROCARDIOGRAPHY MONITORING AND REIMBURSEMENT PRACTICES COULD IMPACT ON SURGICAL SITE INFECTIONS AFTER CORONARY ARTERY BYPASS GRAFT SURGERY

    Oct 1, 2018, 00:00

  • PMU37 - INTRODUCTION RATE OF NEW HEMATO-ONCOLOGY DRUGS IN CATALONIA

    Oct 1, 2018, 00:00

  • PHP270 - POPULARITY OF NURSING PROFESSION AMONGST STUDENTS WHO ARE BEFORE THE CAREER CHOICE

    Oct 1, 2018, 00:00

  • QL3 - EQ-5D-5L IS MORE RESPONSIVE THAN EQ-5D-3L TO TREATMENT BENEFIT OF CATARACT SURGERY

    Oct 1, 2018, 00:00

  • PMD178 - GLOBAL BURDEN OF PRESBYOPIA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRS51 - COMPARISON OF THE TREATMENT OPTIONS FOR COW'S MILK PROTEIN ALLERGY- A COST MINIMIZATION ANALYSIS BASED ON REAL WORLD CONDITIONS OF TURKEY

    Oct 1, 2018, 00:00

  • PHP19 - ANALYSIS OF ONE-DAY SURGERY INTERVENTIONS AMONG PATIENTS UNDER THE AGE OF 18 IN HUNGARY

    Oct 1, 2018, 00:00

  • PCV69 - COST-EFFECTIVENESS OF IVABRADINE AS A PHARMACOTHERAPY OPTION FOR PATIENTS WITH CONGESTIVE HEART FAILURE- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PSY178 - FACTORS ASSOCIATED WITH OBESITY IN GREECE

    Oct 1, 2018, 00:00

  • PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAIN

    Oct 1, 2018, 00:00

  • PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE

    Oct 1, 2018, 00:00

  • PMS87 - IMPACT OF SERIOUS ILLNESS MEDICAL ASSISTANCE POLICY ON PERSISTENCE WITH TERIPARATIDE IN OSTEOPOROSIS PATIENTS IN QINGDAO, CHINA

    Oct 1, 2018, 00:00

  • PCN370 - COMPARISONS ON THE CHANGE OF PSYCHOSOCIAL ILLNESS IMPACT ACROSS FOUR CANCER SURVIVORS

    Oct 1, 2018, 00:00

  • PCN323 - PERJETA TREATMENT DURATION IN THE ITALIAN CLINICAL PRACTICE- A FIRST ANALYSIS OF THE AIFA PRESCRIPTION REGISTRY

    Oct 1, 2018, 00:00

  • PND134 - THE EFFECT OF PHYSICAL ACTIVITY ON THE MOTOR ASPECTS OF DAILY LIVING OF PARKINSON’S DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PHP212 - A DECADE OF PUBLIC-PRIVATE PARTNERSHIPS (PDPS) IN BRAZIL- AN EXPLORATORY ANALYSIS OF PROGRESS AND CHALLENGES

    Oct 1, 2018, 00:00

  • PMU96 - DUTCH HEALTH STATE UTILITIES FOR INFERTILITY AND SUBFERTILITY

    Oct 1, 2018, 00:00

  • PND113 - HEALTH TECHNOLOGY ASSESSMENT OF MRGFUS FOR THE TREATMENT OF ESSENTIAL TREMOR IN THE ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PMS47 - COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN

    Oct 1, 2018, 00:00

  • PMD46 - COST-COST MODEL FOR RULING OUT CORONARY ARTERY DISEASE IN SYMPTOMATIC PATIENTS WITH ULTRA-SENSITIVE PHONOCARDIOGRAPHY IN THE GERMAN AMBULATORY SECTOR

    Oct 1, 2018, 00:00

  • PHP106 - IMPACT OF ACCESS RESTRICTION ON USE OF SHORT-ACTING PRESCRIPTION OPIOIDS IN A US HEALTH PLAN

    Oct 1, 2018, 00:00

  • PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESS

    Oct 1, 2018, 00:00

  • QL4 - ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH METASTATIC MELANOMA IN REAL CLINICAL PRACTICE IN FRANCE

    Oct 1, 2018, 00:00

  • PCN240 - ALL-COMERS VS. BIOMARKER BASED PATIENT SELECTION FOR BIOTHERAPIES IN ONCOLOGY- IMPACT ON DRUG DEVELOPMENT AND MARKET ACCESS

    Oct 1, 2018, 00:00

  • PCN93 - ECONOMIC MODELING FOR THE US OF INTRAVENOUS VS SUBCUTANEOUS RITUXIMAB IN NON-HODGKIN’S LYMPHOMA TREATED WITH R-CHOP

    Oct 1, 2018, 00:00

  • PRM79 - WEBER EFFECT- AN EXTENDED ANALYSIS FOR TEN YEARS OF REPORTING TRENDS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

    Oct 1, 2018, 00:00

  • PCV58 - HEALTH INSURANCE TREATMENT COST OF SECONDARY HYPERTENSION IN HUNGARY- A NATIONWIDE COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PMU34 - PRICE ANALYSIS OF VACCIENS MARKETED IN THE GULF COOPERATION COUNCIL COUNTRIES- A CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PDB27 - CLINICAL INERTIA IN RELATION TO BARRIERS TO PROGRESSION TO INJECTABLE THERAPY IN TYPE 2 DIABETES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCP55 - REVIEW AND RECOMMENDATIONS OF ENDPOINTS FOR REAL-WORLD STUDIES IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PMS8 - REAL-WORLD USE OF PROPHYLACTIC ANTIBIOTICS IN TOTAL KNEE ARTHROPLASTY

    Oct 1, 2018, 00:00

  • PRM132 - MODELING MULTIPLE CARDIOVASCULAR EVENT HISTORY USING NESTED PARTITIONED SURVIVAL MODELS

    Oct 1, 2018, 00:00

  • PMD179 - PATIENTS’ USABILITY OF SIX MOST USED DRY-POWDER INHALERS IN ASTHMA AND COPD

    Oct 1, 2018, 00:00

  • PMH8 - DEPRESSION IS ASSOCIATED WITH CHRONIC DISORDERS IN CHILDREN AND ADOLESCENTS

    Oct 1, 2018, 00:00

  • PCV115 - QUALITY OF INR CONTROL AND SWITCHING TO DOAC BETWEEN WOMEN AND MEN WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS IN SPAIN. A POPULATION-BASED, REAL-WORLD STUDY.

    Oct 1, 2018, 00:00

  • PHP26 - EVOLUTION OF SICK PAY BENEFITS IN HUNGARY BETWEEN 2005 AND 2016

    Oct 1, 2018, 00:00

  • PHP183 - PRICE DIFFERENCE OF MEDICINES DISPENSED IN COMMUNITY PHARMACIES AND IN THE HOSPITAL SECTOR - AN ANALYSIS ON THE MEDICINES FINANCED ON THE BASIS OF HOSPITAL SERVICE TARIFFS

    Oct 1, 2018, 00:00

  • PCN222 - TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILISATION (HCRU) IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) IN CANADA AND EUROPE

    Oct 1, 2018, 00:00

  • PSY142 - THE ACCESS (TIMING AND AVAILABILITY) OF ORPHAN MEDICINE USE AND ITS DETERMINANTS AMONG OECD COUNTRIES FROM 2006 THROUGH 2016

    Oct 1, 2018, 00:00

  • PSY66 - AN EFFICIENT AMBULATORY SERVICE MODEL FOR HEMOPHILIC PATIENTS, A COST-BENEFIT APPROACH

    Oct 1, 2018, 00:00

  • PDB59 - COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC (IDEG) U100 FROM CURRENTLY AVAILABLE BASAL INSULINS IN BELGIUM BASED ON EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PMU32 - ORPHAN DRUG PRICES IN EUROPE- IMPACT OF EXTERNAL REFERENCE PRICING

    Oct 1, 2018, 00:00

  • PSY185 - ALTERNATIVE METHODOLOGIES IMPLEMENTED BY HTA AGENCIES FOR ORPHAN DRUGS- A SCOPING REVIEW

    Oct 1, 2018, 00:00

  • PMH7 - DURATION OF INABILITY TO WORK IN DEPRESSION PATIENTS TREATED IN GENERAL OR PSYCHIATRIC PRACTICES IN GERMANY

    Oct 1, 2018, 00:00

  • PRM150 - TECHNOLOGY DIFFUSION IN HEALTHCARE- INSIGHTS FROM AN AGENT-BASED SIMULATION

    Oct 1, 2018, 00:00

  • PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS- NOT ALWAYS A NICE OUTCOME

    Oct 1, 2018, 00:00

  • PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALY

    Oct 1, 2018, 00:00

  • PHP70 - COUNTRY-SPECIFIC DRIVERS AND BARRIERS FOR MARKET ACCESS OF E-HEALTH SOLUTIONS

    Oct 1, 2018, 00:00

  • PMH60 - A COST-UTILITY ANALYSIS OF A MENTAL HEALTH PROMOTION PROGRAM IN SOCIAL ECONOMY COMPANIES IN FLANDERS

    Oct 1, 2018, 00:00

  • PHP300 - HEALTH TECHNOLOGY ASSESSMENT ROADMAP FOR UKRAINE - THE PERSPECTIVE OF STAKHOLDERS ON CURRENT STATUS AND FUTURE OPPORTUNITIES

    Oct 1, 2018, 00:00

  • PRM219 - A NOVEL MEASURE OF DRUG BENEFIT-RISK ASSESSMENT BASED ON SCALE LOSS SCORE (SLOS)

    Oct 1, 2018, 00:00

  • PMU110 - EXPLORING U.S. CONSUMERS’ KNOWLEDGE, ATTITUDES AND PRACTICES TOWARDS OVER-THE-COUNTER MEDICATIONS

    Oct 1, 2018, 00:00

  • PRM256 - ADJUSTMENT FOR THE IMPACT OF SUBSEQUENT THERAPIES NOT AVAILABLE IN UK ON OVERALL SURVIVAL (OS) IN CASTOR TRIAL- A SUBGROUP ANALYSIS IN SECOND-LINE (2L) PATIENTS

    Oct 1, 2018, 00:00

  • PMD40 - THE BUDGET IMPACT AND COST-CONSEQUENCE OF TREATING LEG ULCERS WITH URGOSTART

    Oct 1, 2018, 00:00

  • PRM184 - ANALYSIS OF UTILITY VALUES USED IN NICE APPRAISALS OF HIGHLY SPECIALISED TECHNOLOGIES

    Oct 1, 2018, 00:00

  • PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING- A RETROSPECTIVE STUDY

    Oct 1, 2018, 00:00

  • PMU26 - BUDGET IMPACT ANALYSIS OF INTRAVENOUS BIOSIMILARS COMPARED WITH INTRAVENOUS ORIGINATORS AND SUBCUTANEOUS PRODUCTS

    Oct 1, 2018, 00:00

  • PMD113 - COST–UTILITY OF SURGICAL SUTURELESS BIOPROSTHESES VS. TAVI IN AORTIC VALVE REPLACEMENT FOR PATIENTS AT INTERMEDIATE AND HIGH SURGICAL RISK

    Oct 1, 2018, 00:00

  • PMD11 - STAGING INVESTIGATION STRATEGIES FOR DISTANT METASTASES DETECTION IN WOMEN WITH BREAST CANCER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PRS44 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD- COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

    Oct 1, 2018, 00:00

  • PCN131 - ASSESSING THE REAL-WORLD COST OF CARE IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCV54 - ESTIMATED ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN GERMANY, ITALY, AND THE UK

    Oct 1, 2018, 00:00

  • PMD130 - HEALTH TECHNOLOGY ASSESSMENT (HTA) OF MEDICAL DEVICES IN EUROPE- THE CALM BEFORE THE STORM OR ALREADY WIND FORCE 8?

    Oct 1, 2018, 00:00

  • PRM97 - PATIENT VERSUS TREATMENT LINE LEVEL MATCHING- IMPACT ON COVARIATES BALANCE AND COST EFFECTIVENESS RESULTS, A CASE STUDY IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PMD126 - DO OUTCOMES DIFFER BY THE TYPE OF ACUTE ISCHEMIC DIAGNOSIS? A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PSS54 - ETHICAL VALIDATION PROCESS FOR VIDEO RECORDED QUALITATIVE INTERVIEWS- EXPERIENCE FROM A RESEARCH PROJECT IN DERMATOLOGY IN FRANCE AND CANADA

    Oct 1, 2018, 00:00

  • PSY157 - EMERGING RHEUMATOID ARTHRITIS AND PSORIASIS BIOLOGICS- HOW TO THRIVE IN THE FACE OF BIOSIMILAR COMPETITION?

    Oct 1, 2018, 00:00

  • PMD182 - DISCRETE CHOICE EXPERIMENTS TO MEASURE PATIENTS' PREFERENCES FOR CORONARY REVASCULARIZATION.

    Oct 1, 2018, 00:00

  • PND129 - SATISFACTION AND EXPERIENCES OF PATIENTS TAKING FINGOLIMOD AND INVOLVED IN A PHARMACY-BASED PATIENT SUPPORT PROGRAM – SATFINO QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PHP160 - PRESCRIPTION CHARGES IN SCOTLAND- THE IMPACT OF FREE PRESCRIPTIONS

    Oct 1, 2018, 00:00

  • PMU53 - HOSPITAL COSTS OF SPINAL LUMBAR FUSION SURGERIES WITH NEUROMONITORING

    Oct 1, 2018, 00:00

  • PND4 - CLOBAZAM AS INTERMITENT PROPHYLAXIS IN TYPICAL FEBRILE SEIZURES AND THEIR ANEMIC STATUS

    Oct 1, 2018, 00:00

  • PMD23 - EASYPOD™ CONNECT OBSERVATIONAL STUDY (ECOS) – FRENCH CASE HISTORIES AND GROWTH OUTCOMES

    Oct 1, 2018, 00:00

  • PHP103 - OUT-OF-POCKET EXPENDITURE FOR PRESCRIBED AND OVER-THE-COUNTER MEDICATIONS IN GREECE

    Oct 1, 2018, 00:00

  • PHP323 - ESTABLISHING AN ALIGNED VIEW OF MODERN, FORWARD-LOOKING HTA PROCESS

    Oct 1, 2018, 00:00

  • PCN201 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN LUNG CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PSS60 - UTILITY ASSESSMENT FOR PEMPHIGUS HEALTH STATES USING VISUAL ANALOGUE SCALE AND TIME TRADE-OFF METHODS

    Oct 1, 2018, 00:00

  • PSY41 - OVERALL SURVIVAL AND NON-RELAPSE MORTALITY OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP77 - EFFECT OF NEW INDICATIONS ON THE PRICE DEVELOPMENT OF NEW MEDICINAL PRODUCTS IN GERMANY

    Oct 1, 2018, 00:00

  • PMD18 - IMPACT OF DIFFERENT IOL MATERIALS ON THE INCIDENCE OF ND-YAG LASER CAPSULOTOMY- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCN99 - EVALUATING THE INCREASING STRAIN OF IMMUNOTHERAPIES (PD-1/PD-L1) ON PUBLIC HEALTHCARE SYSTEMS IN T5 + US

    Oct 1, 2018, 00:00

  • PMS31 - SECUKINUMAB AS A MORE EEFICIENT ALTERNATIVE FOR ANKYLOSING SPONDYLITIS TREATMENT- A COST PER RESPONDER ANALYSIS FROM KOREAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSS59 - CLINICAL CHARACTERISTICS OF BIOLOGIC ELIGIBLE HIDRADENITIS SUPPURATIVA PATIENTS IN EU5

    Oct 1, 2018, 00:00

  • PCN40 - A RETROSPECTIVE STUDY ON PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PRESCRIBED ABIRATERONE ACETATE + PREDNISONE PRIOR TO CHEMOTHERAPY IN SWEDEN, NORWAY AND DENMARK

    Oct 1, 2018, 00:00

  • PSY81 - DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RELAPSED OR REFRACTORY IN ARGENTINA

    Oct 1, 2018, 00:00

  • PMD80 - IS SCREENING FOR OVARIAN CANCER EFFECTIVE AND COST EFFECTIVE IN AUSTRIA? A MODEL-BASED ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PMS97 - THE EFFECT OF NEUROMUSCULAR AND NEUROMUSCULAR-CORE TRAINING ON INJURY PREVENTION

    Oct 1, 2018, 00:00

  • PCV123 - ECONOMIC EVALUATION FOR ROSUVASTATIN VS. ATORVASTATIN IN EGYPTIAN PATIENTS WITH HYPERLIPIDEMIA EGYPT CASE

    Oct 1, 2018, 00:00

  • PMU15 - ANALYSIS OF THE METHODOLOGICAL OBJECTIONS REGARDING INDIRECT TREATMENT COMPARISON SUBMITTED TO THE HAUTE AUTORITÉ DE SANTÉ (HAS)

    Oct 1, 2018, 00:00

  • PHP302 - HOW AFFORDABILITY IS CONSIDERED FOR PRICING POLICIES?

    Oct 1, 2018, 00:00

  • PND25 - ECONOMIC ANALYSIS OF COMPREHENSIVE REHABILITATION EFFICIENCY WITH AND WITHOUT BOTULINUM NEUROTOXIN A INJECTIONS IN CHILDREN WITH SPASTIC CEREBRAL PALSY

    Oct 1, 2018, 00:00

  • PCN388 - PATIENT REPORTED OUTCOMES IN THE CASTRATION RESISTANT PROSTATE CANCER REGISTRY (PRO-CAPRI) IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PMD100 - ECONOMIC EVALUATION OF PROTHROMBIN TIME TEST STRIPS (COAGUCHEK PRO II)

    Oct 1, 2018, 00:00

  • PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA

    Oct 1, 2018, 00:00

  • PRM212 - PATIENT EXPERIENCE WITH PLATINUM-RESISTANT OR PLATINUM-REFRACTORY OVARIAN CANCER

    Oct 1, 2018, 00:00

  • PMD4 - SYSTEMATIC REVIEW AND META-ANALYSIS OF DIAGNOSTIC TEST ACCURACY STUDIES- FLUORESCENCE ENZYME IMMUNOASSAY VERSUS INDIRECT IMMUNOFLUORESCENT ASSAYS FOR INITIAL SCREENING FOR CONNECTIVE TISSUE DISEASES

    Oct 1, 2018, 00:00

  • PCV4 - NON CARDIOVASCULAR COMORBITY AND PROGNOSIS OF CONGESTIVE HEART FAILURE

    Oct 1, 2018, 00:00

  • PHP173 - PHARMACEUTICAL PROCUREMENT IN UKRAINE- AN ANALYSIS OF NEW TRENDS IN IMPROVING ACCESS TO MEDICINES

    Oct 1, 2018, 00:00

  • PMU56 - ECONOMIC EVALUATION OF POSACONAZOLE IN COMPARISON WITH LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF MUCORMYCOSIS IN IRAN

    Oct 1, 2018, 00:00

  • PIN2 - IMPACT OF ADHERENCE TO HEDIS MEASURES ON THE QUALITY OF CARE FOR PEDIATRIC PATIENTS WITH PHARYNGITIS- EVIDENCE FROM A LARGE HEALTH PLAN

    Oct 1, 2018, 00:00

  • PGI7 - ROBUST ESTIMATES CONCERNING THE HCV ELIMINATION STRATEGY IN GREECE. COMBINING THE RESULTS FROM TWO DIFFERENT MATHEMATICAL MODELS

    Oct 1, 2018, 00:00

  • PMH19 - BUDGET IMPACT ANALYSIS OF INHALED LOXAPINE FOR THE MANAGEMENT OF PSYCHOMOTOR AGITATION IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER IN ITALY

    Oct 1, 2018, 00:00

  • PND111 - ELICITING PREFERENCES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS – A BRAZILIAN STUDY USING A MULTICRITERIA DECISION ANALYSIS (MCDA) APPROACH

    Oct 1, 2018, 00:00

  • PRM49 - MEASUREMENT AND VALUATION OF PRODUCTIVITY IN HEALTH ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • PCN123 - EVALUATION OF DRUG THERAPY COSTS FOR PATIENTS WITH BREAST CANCER, MELANOMA AND RENAL CELL CARCINOMA IN MOSCOW IN 2016-2017

    Oct 1, 2018, 00:00

  • PMU78 - MEDICATION THERAPY MANAGEMENT WITH DIRECT PATIENT ENGAGEMENT TO ADDRESS NON-ADHERENCE TO SPECIALTY DRUGS

    Oct 1, 2018, 00:00

  • PRM241 - AN OUT-OF-SAMPLE METHOD TO QUANTIFY SYSTEMATIC ERROR IN UNANCHORED INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PDB88 - ADVENT OF MOBILE PLATFORMS LEVERAGES MULTISTAKEHOLDER COLLABORATION TO DRIVE OUTCOMES IN DIABETES

    Oct 1, 2018, 00:00

  • PMD173 - TREATMENT DIFFERENCES IN CHILDREN BURN CARE IN GERMANY BETWEEN BURN CENTERS AND NON-CENTERS

    Oct 1, 2018, 00:00

  • PCN4 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PND142 - FRENCH DATA FROM A WORLDWIDE PATIENT SURVEY ON ECONOMIC IMPACT OF MIGRAINE

    Oct 1, 2018, 00:00

  • PIH39 - THE ASSOCIATION BETWEEN THE DIFFICULTIES IN THE ENTRANCE EXAM FOR MEDICAL UNIVERSITY AND PHYSICIANS' CAREER CHOICE- EVIDENCE FROM JAPAN

    Oct 1, 2018, 00:00

  • PCN344 - NUTRITION BEHAVIOUR OF PATIENTS WITH BREAST CANCER

    Oct 1, 2018, 00:00

  • PIN107 - BACTERIAL SKIN AND SOFT TISSUE INFECTIONS- GLOBAL MAPPING BY GEOGRAPHICAL DISTRIBUTION AND CLIMATE AREA

    Oct 1, 2018, 00:00

  • PSY105 - COST-UTILITY OF NINTEDANIB VERSUS PIRFENIDONE FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS- A BELGIAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM91 - DATA-DRIVEN AND INSIGHTFUL- AN ANALOGUE ANALYSIS TOOL FOR RAPID AND TARGETED PRICING EXPLORATION

    Oct 1, 2018, 00:00

  • PMH18 - MARKOV MODEL FOR PREDICTING THE RISK OF DEVELOPING DEMENTIA IN ELDERLY ADULTS

    Oct 1, 2018, 00:00

  • PIN123 - USING EQ-5D TO MEASURE QUALITY OF LIFE IN PATIENTS WITH DIABETIC FOOT ULCERS AND VENOUS LEG ULCERS

    Oct 1, 2018, 00:00

  • PRM39 - IS THE CHOICE OF WILLINGNESS-TO-PAY THRESHOLD IN COST-UTILITY ANALYSIS ENDOGENOUS TO THE RESULTING VALUE OF THE TECHNOLOGY?

    Oct 1, 2018, 00:00

  • PRS21 - ECONOMIC IMPACT OF DELAYING INITIATION WITH MULTIPLE INHALER MAINTENANCE TRIPLE THERAPY TREATMENT IN SPANISH COPD PATIENTS

    Oct 1, 2018, 00:00

  • PHP38 - ENZYME REPLACEMENT THERAPIES WITHIN THE GERMAN HTA (AMNOG) PROCESS

    Oct 1, 2018, 00:00

  • PCV76 - COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

    Oct 1, 2018, 00:00

  • PMD29 - BUDGET IMPACT ANALYIS OF MECHANICHAL THROMBECTOMY IN THE TREATMENT OF ACUTE ISCHEMUC STROKE

    Oct 1, 2018, 00:00

  • PMS121 - EVALUATION OF THE WORK PRODUCTIVITY IN ANKYLOSING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PSA) PATIENTS BEFORE AND AFTER THE START OF ADALIMUMAB THERAPY IN DAILY PRACTICE IN BELGIUM (SPACTIVE STUDY)

    Oct 1, 2018, 00:00

  • PCV53 - IS EDOXABAN MORE COST-EFFECTIVE THAN WARFARIN IN PREVENTION OF STROKE AND DEEP VEIN THROMBOSIS?

    Oct 1, 2018, 00:00

  • PMD125 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN FRAGILITY FRACTURE SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN316 - RELATIONSHIP BETWEEN TWO CANCER CLINICAL BENEFIT FRAMEWORKS AND HEALTH TECHNOLOGY DECISIONS IN THREE EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PCV101 - HYPERTRIGLYCERIDEMIA AND RISK OF ALL-CAUSE MORTALITY AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) EVENTS IN CLINICAL PRACTICE- THE TG-REAL STUDY

    Oct 1, 2018, 00:00

  • PSS13 - BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN GREECE

    Oct 1, 2018, 00:00

  • PDB96 - APPLYING MCDA FRAMEWORK IN PHARMACEUTICAL POLICY DECISION MAKING- A PILOT STUDY IN DIABETES MELLITUS TYPE 2

    Oct 1, 2018, 00:00

  • PCP44 - IMPLICATIONS OF GENOME-DRIVEN ONCOLOGY ON EVIDENCE REQUIREMENTS FOR HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PCN271 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH BREAST CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PDB52 - ANNUAL COST OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TURKEY

    Oct 1, 2018, 00:00

  • PRS56 - COST-EFFECTIVENESS OF AMBULATORY OXYGEN IN IMPROVING QUALITY OF LIFE IN FIBROTIC LUNG DISEASE- A TALE OF TWO OUTCOMES

    Oct 1, 2018, 00:00

  • PCN56 - TREATMENT EFFECT MODIFICATION (EM) OF ANTICANCER THERAPIES IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)- A SYSTEMATIC ASSESSMENT OF TRIAL DATA

    Oct 1, 2018, 00:00

  • PMD136 - THE FEASIBILITY OF APPLYING THE MULTIPLE CRITERIA DECISION ANALYSIS FOR THE EVALUATION OF MEDICAL DEVICES IN THE CONTEXT OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT IN TURKEY

    Oct 1, 2018, 00:00

  • PCN84 - TOTAL COST OF CARE AND BUDGET IMPACT FOR PATIENTS WITH CLL TREATED WITH VENETOCLAX

    Oct 1, 2018, 00:00

  • PRM29 - COMPARING OPTHALMOLOGY TREATMENTS VIA THE INTEGRATION OF IPD AND AGGREGATE-LEVEL DATA- WHICH MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) APPROACH IS BEST?

    Oct 1, 2018, 00:00

  • PIN110 - COMPARISON OF DRUG ASSESSMENT REPORTS PUBLISHED BY FRENCH (HAS-CEESP) AND UK (NICE) HTAS- FOCUS ON HEPATITIS C

    Oct 1, 2018, 00:00

  • PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PND110 - GENE THERAPY PRODUCTS – MARKET ACCESS SITUATION IN EU AND IN SLOVAKIA

    Oct 1, 2018, 00:00

  • PHP324 - NICE- A MULTIPROGRAM HTA ORGANIZATION TO SUIT ALL?

    Oct 1, 2018, 00:00

  • MO2 - MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES- AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD2 - STUDY OF STATINS EFFECTS ON COGNITIVE IMPAIRMENT AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT- A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA

    Oct 1, 2018, 00:00

  • PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGAL

    Oct 1, 2018, 00:00

  • PHP131 - WHAT USE IS DISTRIBUTED LEDGER TECHNOLOGY IN REAL-WORLD PRACTICE? - A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALY

    Oct 1, 2018, 00:00

  • PCN147 - COST-EFFECTIVENESS SIMULATION AND ANALYSIS OF COLORECTAL CANCER SCREENING IN SHANGHAI POPULATION, CHINA- COMPARISON BETWEEN URBAN AND RURAL RESIDENTS

    Oct 1, 2018, 00:00

  • PCV152 - TREATMENT BURDEN ASSOCIATED WITH DIFFERENT ANTICOAGULATION STRATEGIES OF ATRIAL FIBRILLATION PATIENTS- AN OBSERVATIONAL STUDY IN GERMANY, SWEDEN AND SWITZERLAND BASED ON THE ANTI-CLOT TREATMENT SCALE

    Oct 1, 2018, 00:00

  • PCN66 - LANDMARK ANALYSES IN ONCOLOGY – SEEING BEYOND THE SURFACE AND PROPOSING A STRUCTURED DATA ANALYSIS CHECKLIST

    Oct 1, 2018, 00:00

  • PCN7 - A TIME WITHOUT SYMPTOMS OR TOXICITY ANALYSIS OF NIRAPARIB COMPARED WITH ROUTINE SURVEILLANCE IN THE MAINTENANCE TREATMENT OF PATIENTS WITH RECURRENT OVARIAN CANCER

    Oct 1, 2018, 00:00

  • PHP174 - ARE FIXED THERAPEUTIC-LEVEL SPENDING CAPS ADVISABLE FOR THE GREEK OUTPATIENT MARKET? METHODOLOGICAL ISSUES AND HEALTH POLICY PROPOSALS

    Oct 1, 2018, 00:00

  • PRM70 - NON-SMALL CELL LUNG CANCER MARKET ANALYSIS FOR TARGETED THERAPIES IN TURKEY

    Oct 1, 2018, 00:00

  • PRS18 - POTENTIAL SAVINGS ACHIEVED THROUGH SWITCHING COPD PATIENTS FROM ICS-CONTAINING REGIMENS TO LAMA+LABA- A SPANISH PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PCP45 - THE ROLE OF CROSSOVER AND TREATMENT SWITCHING IN INDIRECT TREATMENT COMPARSON IN IMMUNO-ONCOLOGY

    Oct 1, 2018, 00:00

  • PMH17 - PREDICTING RECURRENCE OF DEPRESSION USING LIFELOG DATA- A PANEL VAR APPROACH

    Oct 1, 2018, 00:00

  • PHP74 - A REVIEW OF THE INFLUENCE OF INTERNATIONAL REFERENCE PRICING (IRP) ON LAUNCH SEQUENCING IN EUROPE

    Oct 1, 2018, 00:00

  • PIN111 - IMPACT OF VARIATION IN INFLUENZA VACCINATION SCHEDULES AND DECISION-MAKING CRITERIA ON PATIENT OUTCOMES IN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PHP271 - THE GROWING IMPORTANCE OF DIGITAL CHANNELS IN FORMULARY DECISION MAKING IN THE US

    Oct 1, 2018, 00:00

  • PCN105 - ECONOMIC BURDEN OF RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN FRANCE

    Oct 1, 2018, 00:00

  • PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION- A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABAN

    Oct 1, 2018, 00:00

  • PSY174 - IS PHARMACOKINETIC DRIVEN THERAPY OF POTENTIAL BENEFIT IN HEMOPHILIA?

    Oct 1, 2018, 00:00

  • PCN390 - METASTATIC COLORECTAL CANCER (MCRC) - LITERATURE REVIEW ON QUALITY OF LIFE INSTRUMENTS

    Oct 1, 2018, 00:00

  • PIN44 - ECONOMIC EVALUATION OF 60+ YEARS ADULT VACCINATION STRATEGY USING PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN SPAIN

    Oct 1, 2018, 00:00

  • PCN89 - COST –EFFECTIVENESS ANALYSIS OF PERTUZUMAB AS FIRST LINE NEOADJUVANT TREATMENT OPTION FOR PATIENTS HER2 + BREAST CANCER IN REPUBLIC OF MACEDONIA

    Oct 1, 2018, 00:00

  • PHP83 - THE IMPACT OF THE NEW INNOVATIVE ALGORITHM IN ITALY

    Oct 1, 2018, 00:00

  • PMD170 - A RESEARCH ON HOSPITAL BASED-HEALTH TECHNOLOGY ASSESSMENT MODELS OF ACQUISITION OF MEDICAL DEVICES IN HOSPITALS- THE CASE OF TURKEY

    Oct 1, 2018, 00:00

  • PCN124 - DIRECT COST OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR RELAPSED/REFRACTORY (RR) DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS FROM THE FRENCH HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM33 - HUMAN CAPITAL VS. FRICTION COST APPROACH – DIFFERENCES IN THE PRESENCE OF DEATH AND LONG-TERM CONSEQUENCES

    Oct 1, 2018, 00:00

  • PSY162 - EVALUATION OF DIRECT COSTS AND TREATMENT PATTERNS ASSOCIATED WITH THE MANAGEMENT OF NEUROPATHIC PAIN IN COLOMBIA

    Oct 1, 2018, 00:00

  • HT7 - A REVIEW OF EFFICIENCY OPINIONS OF FRENCH ‘HAUTE AUTORITE DE SANTE’ (HAS) IN THE ONCOLOGY FIELD

    Oct 1, 2018, 00:00

  • ND3 - META-ANALYSIS OF REAL-WORLD ADHERENCE AND PERSISTENCE OF MAINTENANCE ONCE- OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS (DIMETHYL FUMARATE, FINGOLIMOD, AND TERIFLUNOMIDE) IN MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PMD58 - A PROSPECTIVE, RANDOMIZED TIME-AND-MOTION STUDY COMPARING RATE OF PROCESSING TECHNIQUES IN AUTOLOGOUS FAT GRAFTING- AN ECONOMIC ANALYSIS

    Oct 1, 2018, 00:00

  • PCV99 - ANALYSIS OF MEAN AGE OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION IN HUNGARY, 2010-2017

    Oct 1, 2018, 00:00

  • PHP216 - HOW RESPONSIVE IS INDUSTRY TO VALUE BASED PROCUREMENT (VBP)?

    Oct 1, 2018, 00:00

  • PRM157 - THE IMPACT OF LANDMARK RESPONSE ON OVERALL SURVIVAL- IMPLICATIONS FOR THE ECONOMIC EVALUATION OF IMMUNE-THERAPY (I-O) TREATMENT IN SMALL CELL LUNG CANCER (SCLC)

    Oct 1, 2018, 00:00

  • PHP89 - CLASS CNN DRUGS IN ITALY- PURCHASE AND PRESCRIPTION BEHAVIOR IN ITALIAN HOSPITALS

    Oct 1, 2018, 00:00

  • PMD181 - PATIENT PREFERENCE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INHALERS- A DISCRETE CHOICE EXPERIMENT (DCE) IN FRANCE

    Oct 1, 2018, 00:00

  • PCV20 - NUMBER NEEDED TO TREAT FOR ORAL ANTI-COAGULANTS VERSUS VKA IN STROKE PREVENTION IN ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PMD14 - PDL1 TESTING PATTERNS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER IN ISRAEL - AN ANALYSIS OF REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PRM58 - IMPACT OF FUTURE COSTS IN COST-EFFECTIVENESS ANALYSES AND A COMPARISON OF DIRECT AND INDIRECT METHODS USING MODELS OF CABAZITAXEL IN PROSTATE CANCER AND CLOPIDOGREL IN ACUTE CORONARY SYNDROME

    Oct 1, 2018, 00:00

  • PRS42 - COST-EFFECTIVENESS OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN BRAZIL

    Oct 1, 2018, 00:00

  • PMD68 - A COST-CONSEQUENCE ANALYSIS OF ANACONDA VERSUS PROPOFOL AND MIDAZOLAM IN THE LONG-TERM SEDATION OF CRITICALLY-ILL SURGICAL PATIENTS FROM THE UK NHS PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN1 - REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF SMALL-CELL LUNG CANCER (SCLC) TREATMENTS- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • AC2 - USE OF MEDICINE PRICING AND REIMBURSEMENT POLICIES FOR UNIVERSAL HEALTH COVERAGE IN INDONESIA

    Oct 1, 2018, 00:00

  • PMS13 - REAL-WORLD TREATMENT OF PATIENTS WITH OSTEOPOROSIS IN GERMANY- PREVALENCE AND INCIDENCE OF PATIENTS WITH OSTEOPOROSIS AT INCREASED FRACTURE RISK

    Oct 1, 2018, 00:00

  • PCP4 - DEVELOMENT OF A QUALITY MANAGEMENT SYSTEM FOR EUNETHTA AND THE PERMANENT EUROPEAN COLLABORATION ON HTA

    Oct 1, 2018, 00:00

  • PP4 - ONE SIZE DOES NOT FIT ALL- HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PMU119 - PATIENT PREFERENCES IN THE TREATMENT OF PERIODONTAL DISEASE- A LATENT CLASS ANALYSIS

    Oct 1, 2018, 00:00

  • PMH32 - ECONOMIC IMPACT OF OPIOID DEPENDENCE IN GERMANY- A COST OF ILLNESS STUDY FOCUSSING ON PATIENTS IN OPIOID MAINTENANCE TREATMENT

    Oct 1, 2018, 00:00

  • PCN135 - DOES PATIENT SELECTION CRITERIA TRANSLATE INTO COST SAVINGS IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER CHEMOTHERAPY FAILURE IN SPAIN?

    Oct 1, 2018, 00:00

  • PCP47 - TAMING THE TORNADO CHART- SIMPLIFYING ONE-WAY SENSITIVITY ANALYSES FOR LARGE-SCALE MULTI-PARAMETER MODELS

    Oct 1, 2018, 00:00

  • PCP67 - REGULATORY REQUIREMENTS AND SCIENTIFIC RATIONALE FOR BIOSIMILAR- US VS. EUROPEAN UNION.

    Oct 1, 2018, 00:00

  • PSY182 - A TARGETED REVIEW OF HAEMATOLOGY SINGLE TECHNOLOGY APPRAISALS (STAS) BY NICE SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)

    Oct 1, 2018, 00:00

  • PMD174 - IMPACT OF MEDICAL DEVICE REGULATION ON FUTURE HTA’S AND REIMBURSEMENT DECISIONS IN GERMANY, FRANCE AND SWITZERLAND – WHAT IS BLOOMING HERE?

    Oct 1, 2018, 00:00

  • PSY107 - COST-EFFECTIVENESS OF BUDESONIDE IN MICROSCOPIC COLITIS PATIENTS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PMS49 - COST-EFFECTIVENESS OF FRACTURE PREVENTION PROVIDED TO ELDERLY LIVING IN THE COMMUNITY

    Oct 1, 2018, 00:00

  • PHP118 - IMPACT OF COHORT TEMPORARY AUTHORISATION FOR USE ON PRICE IN FRANCE

    Oct 1, 2018, 00:00

  • PDB14 - MOBILE APPS FOR MEDICATION ADHERENCE IN DIABETES

    Oct 1, 2018, 00:00

  • PHP249 - ARE TRADITIONAL MANAGED ENTRY AGREEMENTS SUITABLE FOR POTENTIALLY, CURATIVE GENE/CELL THERAPIES?

    Oct 1, 2018, 00:00

  • PHP148 - SELF-PERCEIVED HEALTH INEQUALITIES BY INCOME DISTRIBUTION IN EUROPEAN UNION

    Oct 1, 2018, 00:00

  • PCN212 - PREVALENCE OF CANCER AMONG WOMEN IN A TERTIARY TEACHING HOSPITAL IN LAGOS SOUTHWEST NIGERIA- A PHARMACOEPIDEMIOLOGICAL AND EVIDENCE BASED SURVEY

    Oct 1, 2018, 00:00

  • PSY31 - COMPARISON OF THE ESTIMATED PREVALENCE OF DIAGNOSED HOMOCYSTINURIA AND PHENYLKETONURIA IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCN189 - ANALYSIS COST / UTILITY OF THE THERAPEUTIC THERAPY TREATMENT OF LUNG CANCER IN A UNIVERSITY HOSPITAL OF SPAIN

    Oct 1, 2018, 00:00

  • CN8 - COST-EFFECTIVENESS ANALYSIS OF ORAL CANCER SCREENING IN TAIWAN- A REAL WORLD DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PSY207 - IS LATE NIGHT EATING LINKED TO CHILDHOOD OBESITY? A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PRM191 - LONGITUDINAL CONSTRUCT VALIDITY OF THE HEMOPHILIA CAREGIVER IMPACT MEASURE

    Oct 1, 2018, 00:00

  • MD4 - DIGITAL HEALTHCARE EVALUATION AT NICE- AN EVOLVING PROCESS

    Oct 1, 2018, 00:00

  • PCN352 - UTILITY VALUES FOR ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS IN FRANCE RECEIVING SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH Y-90 RESIN MICROSPHERES VERSUS SORAFENIB USING EQ-5D SCORES MAPPED FROM EORTC-QLQ-C30 RESULTS

    Oct 1, 2018, 00:00

  • PDB100 - STUDY ON AWARENESS REGARDING NEWER TRENDS IN DIABETES MEDICATION MANAGEMENT

    Oct 1, 2018, 00:00

  • PSY171 - EXPECTED AND ACTUAL REIMBURSEMENT BASED ON CLINICAL PRACTICE GUIDELINE RECOMMENDATIONS IN TURKEY

    Oct 1, 2018, 00:00

  • PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • Researchers, Patients, and Stakeholders Evaluating Comparative-Effectiveness Research- A Mixed-Methods Study of the PCORI Reviewer Experience

    Oct 1, 2018, 00:00

  • PMS33 - CATEGORISING PATIENTS WITH RHEUMATOID ARTHRITIS USING TRAJECTORIES OF DISEASE ACTIVITY SCORE IN HUNGARY

    Oct 1, 2018, 00:00

  • PCN229 - COMPARISON OF SICKNESS BENEFIT AND SICK LEAVE DURATION IN ONCOLOGY ACROSS COUNTRIES

    Oct 1, 2018, 00:00

  • PRS8 - EFFECTS OF SMOKIMG CESSATION ON HEALTH OUTCOMES AMONG COPD PATIENTS IN SOUTH KOREA- 12 YEARS FOLLOW-UP

    Oct 1, 2018, 00:00

  • PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?

    Oct 1, 2018, 00:00

  • PRS43 - COST-EFFECTIVENESS OF DOXYCYCLINE VERSUS PLACEBO IN OUTPATIENT-TREATED ACUTE EXACERBATIONS OF COPD- A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PUK15 - PHARMACOECONOMICS MODES OF ANTIBIOTIC THERAPYOF UNCOMPLICATED COMMUNITY-ACQUIRED ACUTE PYELONEPHRITIS IN A MULTIDISCIPLINARY HOSPITALS

    Oct 1, 2018, 00:00

  • PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONG

    Oct 1, 2018, 00:00

  • PCN301 - HEALTH TECHNOLOGY ASSESSMENT FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR CANCER

    Oct 1, 2018, 00:00

  • PHP154 - PRIVATE HEALTH SPENDING AND ACCESS TO HEALTHCARE OF UNEMPLOYED PEOPLE IN GREECE

    Oct 1, 2018, 00:00

  • PCN320 - RECOMMENDATIONS OF SPANISH THERAPEUTIC POSITIONING REPORTS FOR NEW ONCOLOGY DRUGS SINCE YEAR 2013

    Oct 1, 2018, 00:00

  • PDB17 - REAL-WORLD DOSING BEHAVIOURS AND OUTCOMES WHEN SWITCHING TO IDEGLIRA FROM A FREE COMBINATION OF INSULIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY

    Oct 1, 2018, 00:00

  • PMS89 - DEVELOPMENT OF AN OUTCOMES MEASUREMENT TOOL TO EVALUATE THE QUALITY OF BIOLOGIC SWITCH IN PSORIATIC ARTHRITIS

    Oct 1, 2018, 00:00

  • PRM65 - DIFFERENT COST EFFECTIVENESS MODELS USED FOR ECONOMIC EVALUATION IN MODERATE TO SEVERE PAINFUL DIABETIC NEUROPATHY OR POST-HERPETIC NEURALGIA

    Oct 1, 2018, 00:00

  • PHP321 - THE HTA APPROACH OF NOVEL TREATMENTS IN THE CENTRAL EASTERN EUROPEAN COUNTRY FOR FIVE YEARS PERIOD (2013-2017)- THE CASE OF BULGARIA

    Oct 1, 2018, 00:00

  • PSY154 - ECONOMIC BURDEN OF BETA-THALASSEMIA- LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP47 - EVALUATING PATIENTS’, PHYSICIANS’ AND PHARMACISTS’ PERCEPTION REGARDING GENERIC MEDICINES IN GONDAR, NORTHWEST ETHIOPIA

    Oct 1, 2018, 00:00

  • PHP266 - MANAGED ACCESS PROGRAMS- A FIRST STEP FOR UK HTA?

    Oct 1, 2018, 00:00

  • PCN309 - DIVERSITY IN SAFETY DATA ANALYSES IN GERMAN AMNOG BENEFIT ASSESSMENTS FOR MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PSY195 - HUMANISTIC BURDEN ASSOCIATED WITH RPE65 GENE MUTATION RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN142 - COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PRM234 - HAZARD RATIO ESTIMATION USING DIFFERENT METHODS- AN IMPACT ASSESSMENT

    Oct 1, 2018, 00:00

  • PHP341 - ARE THERE ENOUGH REGULATIONS TO COMBAT THE POOR QUALITY POVIDONE-IODINE IN EGYPT

    Oct 1, 2018, 00:00

  • PRM111 - APPLICATION AND ACCEPTANCE OF COMPLEX SURVIVAL EXTRAPOLATION METHODS IN HTA SUBMISSIONS

    Oct 1, 2018, 00:00

  • PRM113 - PREDICTION MODEL FOR IDENTIFYING PATIENTS WITH LIPODYSTROPHY IN ELECTRONIC HEALTH RECORDS

    Oct 1, 2018, 00:00

  • PCN387 - COMPARISON OF EQ-5D-5L AND 15D INSTRUMENTS IN ASSESSING HEALTH-RELATED QUALITY OF LIFE IN BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PMS101 - EVAULATION OF OUTCOMES AND PHYSIOTERAPY REHABILITATION AFTER DIRECT ANTERIOR APPROACH OF TOTAL HIP ARTHROPLASTY COMPARED TO CONVENTIONAL ANTEROLATERAL APPROACH

    Oct 1, 2018, 00:00

  • PSY5 - PATIENTS WITH RELAPSING ANCA-ASSOCIATED VASCULITIS (AAV) EXPERIENCE UNMET NEEDS AND UTILISE SIGNIFICANT HEALTHCARE RESOURCES

    Oct 1, 2018, 00:00

  • PCN151 - COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN THE TREATMENT OF PATIENTS WITH HEPATOCELULLAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCN138 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN ENGLAND

    Oct 1, 2018, 00:00

  • PDB110 - TREATMENT PERSISTENCE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH GLP-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE IN SWEDEN- NATIONWIDE RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND

    Oct 1, 2018, 00:00

  • PMD27 - LENS EXPLANTATION AND LENS EXCHANGE RATES WITH MULTIFOCAL IOLS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • A Generic Model for Follicular Lymphoma- Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data

    Oct 1, 2018, 00:00

  • PRM180 - COMPARING QALYS GENERATED FOR THE EQ-5D-3L AND EQ-5D-5L IN A LONGITUDINAL STUDY OF CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PSS43 - DUPILUMAB IMPROVES ABSENTEEISM IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS COMPARED WITH PLACEBO IN PHASE 3 LIBERTY AD SOLO STUDIES

    Oct 1, 2018, 00:00

  • PSY63 - COST BY OUTCOMES ANALYSIS OF NOVEL TRIPLE-COMBINATION THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN BRAZIL

    Oct 1, 2018, 00:00

  • PSY27 - SPINAL MUSCULAR ATROPHY- A REVIEW OF EPIDEMIOLOGY, BURDEN AND UNMET NEEDS

    Oct 1, 2018, 00:00

  • PUK29 - RENAL SEVERITY IN PATIENTS WITH LUPUS NEPHRITIS AT DIAGNOSIS FOR SYSTEMIC LUPUS ERYTHEMATOSUS

    Oct 1, 2018, 00:00

  • PRM102 - ANALYZING REAL-WORLD DATA TO TARGET HARD-TO-IDENTIFY PATIENT POPULATIONS FOR CLINICAL TRIALS- A CASE STUDY IN METASTATIC BREAST CANCER

    Oct 1, 2018, 00:00

  • PRM240 - ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY OF ORAL CANCER PATIENTS- INTEGRATION OF LIFETIME SURVIVAL ADJUSTED WITH REPEATED QUALITY OF LIFE MEASUREMENTS

    Oct 1, 2018, 00:00

  • PCN341 - ESTIMATION OF UTILITIES ON SKELETAL-RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTATIC CANCER IN KOREA

    Oct 1, 2018, 00:00

  • MD1 - EVIDENCE DEVELOPMENT TIMELINE OF MEDICAL DEVICES IN THE UK- WHERE DO MEDICAL INNOVATION BRIEFINGS FIT?

    Oct 1, 2018, 00:00

  • PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTS

    Oct 1, 2018, 00:00

  • PMD20 - COMPARATIVE STUDY OF SPINE ANTERIOR LUMBAR INTERBODY FUSION DEVICES

    Oct 1, 2018, 00:00

  • PRS29 - COST ANALYSIS OF AN ERROR TARGETED INTERVENTION TO REDUCE OR ERADICATE INHALER ERRORS IN ASTHMA PATIENTS IN THE UK

    Oct 1, 2018, 00:00

  • PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM271 - REDUCING LENGTH OF AN OUTCOMES-BASED CONTRACT THROUGH ACTIVE-LEARNING BY PAYERS

    Oct 1, 2018, 00:00

  • PCV146 - SYSTEMATIC LITERATURE REVIEW OF UTILITY DECREMENTS ASSOCIATED WITH THE NON-FATAL MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

    Oct 1, 2018, 00:00

  • PIN53 - IS THE RECOMBINANT ZOSTER VACCINE ALSO COST-EFFECTIVE FOR THE GERMAN POPULATION ≥50 YEARS OF AGE?

    Oct 1, 2018, 00:00

  • PCN83 - THE USE OF OBINUTUZUMAB IN TREATMENT OF REFRACTORY AND RELAPSING FOLLICULAR LYMPHOMA

    Oct 1, 2018, 00:00

  • PHP303 - WHAT ARE THE KEY CONSIDERATIONS FOR SEEKING PAYER SCIENTIFIC ADVICE IN THE EU?

    Oct 1, 2018, 00:00

  • PDB87 - A COST-OF-CONTROL ANALYSIS- ONCE-WEEKLY SEMAGLUTIDE REDUCES COST OF REACHING TREATMENT TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN NORWAY

    Oct 1, 2018, 00:00

  • PDB11 - CHART REVIEW ANALYSIS OF INSULIN GLARGINE 300 AND INSULIN GLARGINE 100 USE IN FRANCE, SPAIN, AND GERMANY

    Oct 1, 2018, 00:00

  • PIN115 - BARRIERS TO ACCESS AND IMPLEMENTATION OF ROTAVIRUS VACCINATION IN EUROPE

    Oct 1, 2018, 00:00

  • PMD25 - RISK FACTORS ASSOCIATED WITH PCO FOLLOWING CATARACT SURGERY- REAL-WORLD OUTCOMES STUDY IN THE UNITED KINGDOM (UK)

    Oct 1, 2018, 00:00

  • CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML)- A FRENCH PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP194 - THE EMA CLINICAL DATA WEBSITE- A CONCEPTUAL EXPLORATORY APPROACH TO BENCHMARK CLINICAL DEVELOPMENT INDICATORS IN MARKETING AUTHORIZATIONS

    Oct 1, 2018, 00:00

  • PHP261 - IMPACT OF DYNAMIC CHANGES OF THE DEFINITION OF THE APPROPRIATE COMPARATIVE THERAPY (ACT) ON MARKET ACCESS PERFORMANCE OF NEW ACTIVE SUBSTANCES IN GERMANY

    Oct 1, 2018, 00:00

  • PMH14 - SOCIAL FUNCTIONING AT ADMISSION IN PATIENTS WITH MENTAL ILLNESS HOSPITALIZED COMPULSORILY BY PREFECTURAL GOVERNORS IN ACCORDANCE WITH THE PROVISIONS OF ARTICLE 29 OF THE JAPANESE MENTAL HEALTH ACT.

    Oct 1, 2018, 00:00

  • PCN44 - FIRST-LINE TREATMENT EFFICACY IN EGFR-POSITIVE NON-SMALL CELL LUNG CANCER- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PDB82 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM (DPP) 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER QALY CALCULATIONS MAY REVIVE ITS METFORMIN CONCLUSIONS

    Oct 1, 2018, 00:00

  • PSY64 - BLEEDING EPISODES, THE MOST IMPACTFUL VARIABLE IN THE TREATMENT COST OF THE HEMOPHILIA A IN COLOMBIA. DATA FROM THE LITERATURE AND THE REAL LIFE

    Oct 1, 2018, 00:00

  • PGI24 - COST-UTILITY ANALYSIS OF VITAMINE E AND PIOGLITAZONE IN ADDITION TO 2 YEARS OF LIFE-STYLE MODIFICATION THERAPY FOR NON-ALCOHOLIC STEATOHEPATITIS PATIENTS IN JAPAN

    Oct 1, 2018, 00:00

  • PRM50 - IMPROVEMENT OF EFFICIENCY OF SEVERE ATOPIC ASTHMA TREATMENT

    Oct 1, 2018, 00:00

  • PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHN’S DISEASE

    Oct 1, 2018, 00:00

  • PSY46 - A DYNAMIC APPROACH FOR BUDGET IMPACT ANALYSIS (BIA) IN ONCOLOGY – THE CASE OF NOVEL TREATMENT COMBINATIONS FOR FRONTLINE TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TIE NDMM)

    Oct 1, 2018, 00:00

  • PCN270 - HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH 6 PREVALENT CANCER IN SPAIN, A REALWORLD DATA STUDY

    Oct 1, 2018, 00:00

  • PMD175 - MARKET ENTRY OF NEW MEDICAL DEVICES IN GERMANY - OUTPATIENT SECTOR

    Oct 1, 2018, 00:00

  • PRS45 - COST-EFFECTIVENESS OF BEDAQUILINE VERSUS INJECTABLE STANDARD-OF-CARE AGENTS FOR THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) IN RUSSIA, INDIA, AND SOUTH AFRICA- BREAKTHROUGH INNOVATION DRIVING DOWN COST OF TREATMENT SUCCESS

    Oct 1, 2018, 00:00

  • PGI47 - OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES IN IRRITABLE BOWEL SYNDROME PATIENTS- A RETROSPECTIVE ANALYSIS OF A LARGE U.S. ELECTRONIC HEALTH RECORD DATABASE

    Oct 1, 2018, 00:00

  • PRM125 - SYSTEMATIC REVIEW OF META-MODELING APPLICATIONS AND OPPORTUNITIES FOR ADVANCED ANALYSES WITH HEALTH ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PRM169 - RESPONSIVENESS OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS FOLLOWING TOTAL HIP OR KNEE REPLACEMENT

    Oct 1, 2018, 00:00

  • PCV44 - EFFECTIVENESS OF SACUBITRIL/VALSARTAN VERSUS ENALAPRIL IN REDUCING MORTALITY AND HOSPITALIZATIONS COSTS FROM A MOROCCAN HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMH39 - HEALTH-ECONOMIC EVALUATION OF PHARMACOGENETIC TESTS IN PSYCHIATRIC IN-PATIENT CARE

    Oct 1, 2018, 00:00

  • PHP268 - THE HUNGARIAN PALLIATIVE CARE POSITION, CHALLENGES, BREAK POINTS

    Oct 1, 2018, 00:00

  • PRS46 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI IN PATIENTS WITH COPD- COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

    Oct 1, 2018, 00:00

  • PSS66 - IDENTIFYING THE MOST SUITABLE QUALITY OF LIFE ASSESSMENT TOOLS TO MEASURE HUMANISTIC BURDEN OF ACUTE OTITIS MEDIA IN CHILDREN

    Oct 1, 2018, 00:00

  • PRM4 - A CASE STUDY IN CHOOSING WISELY RECOMMENDATION ADOPTION- SINGLE FRACTION RADIATION TREATMENT OF BONE METASTASES

    Oct 1, 2018, 00:00

  • PHP220 - OLD DRUGS TURNED NEW FOR ULTRA ORPHAN DISEASE- A CHALLENGE FOR PAYERS OR FOR THE INDUSTRY?

    Oct 1, 2018, 00:00

  • PRM118 - ADJUSTMENT FOR SUBSEQUENT THERAPIES RECEIVED- THE IMPACT ON OUTCOMES OF AN ECONOMIC MODEL OF NIVOLUMAB+IPILIMUMAB IN FIRST LINE RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMH24 - COST IMPLICATIONS OF ANTIPSYCHOTICS DRUGS- A HOSPITAL BUDGET IMPACT MODEL

    Oct 1, 2018, 00:00

  • PSY70 - MANAGEMENT COSTS OF CHEMOTHERAPY AND ALLOGENEIC STEM-CELL TRANSPLANT OF CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FRANCE

    Oct 1, 2018, 00:00

  • PCN205 - OUTCOMES OF DECISION AIDS USED IN ONCOLOGY- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PHP203 - RELATIVE VALUE OF EVIDEM MCDA FRAMEWORK FOR REFLECTIVE DRUG EVALUATION AMONG HOSPITAL PHARMACISTS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCP50 - PERFORMANCE INDICATORS IN THE MONITORING OF OUTSOURCED PUBLIC HEALTH SERVICES

    Oct 1, 2018, 00:00

  • PMS100 - COMPARISON OF LOW AND HIGH TOP BASKETBALL SHOES WITH RESERVE PLAYERS

    Oct 1, 2018, 00:00

  • PCV3 - IMPROVING ASPIRIN TOXICITY THROUGH PRECISION MEDICINE

    Oct 1, 2018, 00:00

  • PMS20 - BUDGET IMPACT OF INTRODUCING SECUKINUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2018, 00:00

  • PMU122 - PATIENT-REPORTED OUTCOMES ON PERCEIVED WELL-BEING AMONG PATIENTS ON ANTI-INFLAMMATORY TREATMENT

    Oct 1, 2018, 00:00

  • PMD59 - DEVELOPING A COMPREHENSIVE TREATMENT COST COMPARISON MODEL IN SICKLE CELL DISEASE

    Oct 1, 2018, 00:00

  • PCP18 - EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT- A MARKER OF HTA FAILURE?

    Oct 1, 2018, 00:00

  • PSS40 - COST-EFFECTIVENESS OF OCRIPLASMIN FOR THE TREATMENT OF VITREOMACULAR TRACTION, INCLUDING WHEN ASSOCIATED WITH MACULAR HOLE- A BELGIAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD167 - HEALTH TECHNOLOGY ASSESSMENT OF MOBILE HEALTH APPLICATIONS- SLOW PROGRESS IN A FAST-PACED INDUSTRY?

    Oct 1, 2018, 00:00

  • PHP322 - REAL-WORLD DATA - WHAT ARE THE USE AND REQUIREMENTS IN HEALTH-ECONOMIC APPRAISALS IN REINSCRIPTION BY THE FRENCH HAUTE AUTORITE DE SANTE (HAS)?

    Oct 1, 2018, 00:00

  • PMS3 - INFLIXIMAB FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUG-NAIVE RHEUMATOID ARTHRITIS PATIENTS- SYSTEMATIC REVIEW AND DESCRIPTIVE ANALYSIS OF PUBLICATIONS OF RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PMD38 - CELL-FREE FETAL DNA AS A CONTINGENT PRENATAL SCREENING OF TRISOMIES CONDITIONAL TO A RISK ≥ 1-1,000 FOR ITALIAN PREGNANT WOMEN- AN ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PMS23 - OPTIMIZING TREATMENT FOR RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA (OPTRA)

    Oct 1, 2018, 00:00

  • PDB135 - THE BURDEN OF DIABETES MELLITUS IN TAIWAN BASED ON PATIENT-REPORTED OUTCOMES

    Oct 1, 2018, 00:00

  • PMD114 - ASSESSING AND MODELING ORGANIZATIONAL IMPACT OF TILMANOCEPT IN PERFORMING SENTINEL LYMPH NODE BIOPSY IN FRANCE

    Oct 1, 2018, 00:00

  • PMU42 - ECONOMIC AND ORGANIZATIONAL IMPACT OF A VASCULAR ACCESS TEAM IN AN ITALIAN HOSPITAL

    Oct 1, 2018, 00:00

  • PCN371 - HEALTH RELATED QUALITY OF LIFE IN CERVIX-UTERI CANCER WOMEN TREATED IN A MEXICAN THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PCN287 - ANALYSIS OF IMPACTS OF THE SUPPLEMENTARY SCHEMES ON THE DRUG REIMBURSEMENT DECESION-MAKING UNDER THE POSITIVE LIST SYSTEM IN KOREA

    Oct 1, 2018, 00:00

  • PSY215 - MEASURING QUALITY OF LIFE FOR ECONOMIC EVALUATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD) FROM CHILDHOOD TO ADULTHOOD- PROTOCOL FOR A NEW PREFERENCE-BASED MEASURE

    Oct 1, 2018, 00:00

  • PCN191 - COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN

    Oct 1, 2018, 00:00

  • PDB105 - INCREASED BURDEN OF MULTIMORBIDITY AMONGST DIABETES PATIENTS- A MULTINATIONAL SURVEY

    Oct 1, 2018, 00:00

  • PHP214 - SHOULD DRUG PRICES DIFFER BY INDICATION? OUTLINING THE DEBATE ON INDICATION-BASED PRICING AND HOW IT HAS BEEN IMPLEMENTED

    Oct 1, 2018, 00:00

  • PSY103 - MODELLING AVERAGE COST AND COST-PER-RESPONDER FOR BIOLOGICAL TREATMENTS FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS WITH DOSE ESCALATION AND REAL-WORLD DRUG SURVIVAL

    Oct 1, 2018, 00:00

  • PCN325 - COMPARING THE ROLE OF DIFFERENT SPECIALITIES IN THE MANAGEMENT OF PROSTATE CANCER IN FRANCE AND ITALY- INSIGHTS FROM A REAL-WORLD STUDY

    Oct 1, 2018, 00:00

  • PDB131 - LATENT CLASS ANALYSIS FOR PERSONALIZED DIABETES MANAGEMENT- ONE SIZE DOES NOT FIT ALL?

    Oct 1, 2018, 00:00

  • PRS41 - COST-EFFECTIVENESS OF PIRFENIDONE FOR THE TREATMENT OF PATIENTS WITH MILD TO MODERATE IDIOPATHIC PULMONARY FIBROSIS IN GREECE

    Oct 1, 2018, 00:00

  • PIN67 - COST-EFFECTIVENESS OF QUADRIVALENT INFLUENZA VACCINATION IN GERMANY

    Oct 1, 2018, 00:00

  • PSY85 - ECONOMIC BURDEN ASSOCIATED WITH RPE65 GENE RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP298 - ON THE RIGHT TRACK? EXAMINING NICE’S FAST-TRACK APPRAISAL PROCESS

    Oct 1, 2018, 00:00

  • PMS50 - COST-EFFECTIVENESS ANALYSIS OF APREMILAST IN THE TREATMENT OF PSORIATIC ARTHRITIS (PSA) IN THE SLOVAK REPUBLIC AND SLOVENIA

    Oct 1, 2018, 00:00

  • PSY106 - COST-EFFECTIVENESS OF RARE DISEASES IN SPAIN

    Oct 1, 2018, 00:00

  • PRS58 - PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)- WHAT HAPPENS BEFORE THE DIAGNOSIS? A REAL-WORLD, RETROSPECTIVE, PRIMARY CARE DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PMS41 - COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN GREECE

    Oct 1, 2018, 00:00

  • PSS21 - HEALTH INSURANCE TREATMENT COST OF LICHEN PLANUS IN HUNGARY- COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTAT

    Oct 1, 2018, 00:00

  • PHP257 - AN ANALYSIS AND FEASIBILITY ASSESSMENT OF INDICATION-SPECIFIC PRICING AS A MEANS TO IMPROVE PATIENT ACCESS TO MEDICINES AND REINFORCE INCENTIVES FOR INNOVATION

    Oct 1, 2018, 00:00

  • PMD13 - PREVALENCE OF ISOLATED HYPERTENSION AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PRM264 - DOES THE DESIGN OF A DISCRETE CHOICE ANALYSIS INFLUENCE ITS RESULTS? AN EXAMPLE STUDY OF WOMEN'S PREFERENCES FOR CONTRACEPTIVE PRODUCTS

    Oct 1, 2018, 00:00

  • PCN28 - A REVIEW OF THE EFFECTIVENESS OF PHOTODYNAMIC THERAPY FOR CANCER

    Oct 1, 2018, 00:00

  • PRM9 - A LONGITUDINAL, ITEM-LEVEL ANALYSIS METHODOLOGY TO SUPPORT THE INTERPRETABILITY OF MULTI-ITEM PATIENT-REPORTED OUTCOMES

    Oct 1, 2018, 00:00

  • PRS87 - COMPARABILITY OF A PROVISIONED DEVICE VERSUS BRING YOUR OWN DEVICE FOR COMPLETION OF PATIENT-REPORTED OUTCOME (PRO) MEASURES BY PARTICIPANTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- QUALITATIVE INTERVIEW FINDINGS

    Oct 1, 2018, 00:00

  • PHP329 - THE REGISTRY EVALUATION AND QUALITY STANDARDS TOOL (REQUEST) FOR HEALTH TECHNOLOGY ASSESSMENT FROM AN OUTCOMES ASSESSMENT PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCV48 - TOTAL ANNUAL HEALTHCARE COSTS OF HEART FAILURE BETWEEN 2005 AND 2014- A RETROSPECTIVE, POPULATION-BASED STUDY IN SWEDEN

    Oct 1, 2018, 00:00

  • PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS- SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PDB49 - TYPE 2 DIABETES MELLITUS IN ALGERIA – A COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PUK16 - COST-EFFECTIVENESS OF TOLVAPTAN IN CANADIAN PATIENTS WITH AUTOSOMAL POLYCYSTIC KIDNEY DISEASE- AN ADAPTATION OF THE ADPKD OUTCOMES MODEL

    Oct 1, 2018, 00:00

  • PND69 - COST-UTILITY ANALYSIS OF COMMUNITY OCCUPATIONAL THERAPY IN DEMENTIA (COTID-UK) VERSUS USUAL CARE- RESULTS FROM VALID, A MULTI-SITE RANDOMIZED CONTROLLED TRIAL IN THE UK

    Oct 1, 2018, 00:00

  • PMU123 - THE RELATIONSHIP BETWEEN INDIVIDUAL-LEVEL DEPRIVATION WITH HEALTH-RELATED QUALITY OF LIFE IN THE GENERAL POPULATION

    Oct 1, 2018, 00:00

  • PND130 - MEASURING WHAT MATTERS TO PEOPLE WITH MULTIPLE SCLEROSIS AND PREFERENCES FOR NOVEL METHODS TO ASSESS CLINICAL OUTCOMES

    Oct 1, 2018, 00:00

  • PMS60 - CLINICAL AND ECONOMIC "REAL WORLD” ANALYSIS OF THE SWITCHING FROM REMICADE (INFLIXIMABE) BY REMSIMA (INFLIXIMAB BIOSSIMILAR) OF PLANSERV PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS.

    Oct 1, 2018, 00:00

  • PDB122 - THE EFFECTS OF TYPE 2 DIABETES ON HEALTH-RELATED QUALITY OF LIFE IN THE FINNISH POPULATION AS MEASURED WITH EQ-5D-5L

    Oct 1, 2018, 00:00

  • PCV8 - IMPACT OF EXERCISE-BASED REHABILITATION IN PATIENTS WITH HEART FAILURE (EXTRAMATCH II) ON EXERCISE CAPACITY AND HEALTH-RELATED QUALITY OF LIFE- A META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM RANDOMISED TRIALS

    Oct 1, 2018, 00:00

  • PMD47 - BUDGET IMPACT MODELLING OF POINT-OF-CARE HBA1C MONITORING OF PATIENTS WITH DIABETES MELLITUS TYPE II IN THE UNITED KINGDOM AND AUSTRALIA

    Oct 1, 2018, 00:00

  • PGI30 - POLISH THERAPEUTIC ALGORITHMS IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE

    Oct 1, 2018, 00:00

  • PSS68 - THE MOST INFLUENTIAL DRIVERS OF PSORIASIS PATIENTS’ TREATMENT CHOICE- A DISCRETE CHOICE EXPERIMENT SURVEY IN THE US

    Oct 1, 2018, 00:00

  • PND158 - CHANGES IN SLEEP PATTERNS AFTER VAGUS NERVE STIMULATION, DEEP BRAIN STIMULATION OR EPILEPSY SURGERY- SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BA

    Oct 1, 2018, 00:00

  • PHP187 - BEST PRACTICES FOR REAL WORLD EVIDENCE (RWE) COLLECTION FOR CELL AND GENE THERAPIES

    Oct 1, 2018, 00:00

  • PHP289 - AN EXAMINATION OF DELAYS DURING NICE TECHNOLOGY APPRAISAL REVIEWS

    Oct 1, 2018, 00:00

  • PIN76 - IMPACT OF TRANSFERRING ARTS DISPENSING FROM HOSPITAL TO COMMUNITY PHARMACIES- A PILOT STUDY IN PORTUGAL

    Oct 1, 2018, 00:00

  • PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMEN

    Oct 1, 2018, 00:00
  • «
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58 (current)
  • 59
  • 60
  • »